T-BINGEN, GERMANY and BOSTON, MA/ACCESSWIRE / September 29, 2020 / CureVac NV (NASDAQ: CVAC), a clinically staged biopharmaceutical company that presents a new elegance of messenger ribonucleic acid processor (“mNS”), announced that the first player has been dosed in a phase 2a clinical trial of its COVID-19 candidate vaccine, CVnCoV. The dose confirmation study, entitled CV-NCOV-002, is conducted in Peru and Panama and will recruit a total of 690 healthy players into two distinct groups: those over 61 and younger from 18 to 60 years old.
Participants will receive two vaccines at 28-day intervals. Different dose grades, starting with 6 mg, will be studied to verify protection and evaluate the reactogenicity of the vaccine in the elderly. In addition, in a geographical environment with a high incidence of COVID-19 infection, the fun immune reaction after management of CVnCoV will be evaluated and the protection knowledge base will be expanded to prepare for the start of a Phase 2b/3 study. The first complete knowledge for Phase 2a in the elderly is expected to develop later in the fourth quarter of 2020.
The design of the exam was coordinated and approved by the government of physical fitness and ethics committees of Peru and Panama and is based on the initial knowledge of protection and immunogenicity of the CV-NCOV Phase 1 exam. CureVac 001 underway in fit adult volunteers in Germany and Belgium. Waiting for more knowledge of the ongoing Phase 1 and Phase 2a exam, CureVac plans to launch the Phase 2b/3 global clinical trial that enrolls approximately 30,000 participants in the fourth quarter of 2020.
“The start of the Phase 2a clinical trial in Peru and Panama represents a vital step in our COVID-19 clinical studies program,” dr. Mariola Fotin-Mleczek, Chief Technology Officer, CureVac. ” This trial is designed to further verify the dose variety of our candidate vaccine and verify that we can deliver a tolerable vaccine, also to the elderly, who are at increased risk of experiencing serious COVID-19 effects. “
About CVnCoV
CureVac began the progression of its mNN-based COVID-19 candidate vaccine in January 2020. After extensive preclynic progression, the company began its phase 1 clinical examination of CVnCoV in June 2020 at clinical examination centers in Germany and Belgium. production capacity at its headquarters in Tubinga and is currently expanding those production functions to enable large-scale manufacturing of CVnCoV and other mNR-based vaccines.
About CureVac
CureVac is a clinical-level global biopharmaceutical company in the box of messenger RNA generation (mRNA) with experience in the progression and optimization of this flexible molecule for medical purposes. the human structure to produce its own proteins capable of combating a wide variety of diseases. The company applies its technologies to the progression of prophylactic vaccines, cancer therapies, curative antibodies and the remedy of rare diseases. CureVac is headquartered in Tubingen, Germany, and has locations in Frankfurt and Boston, USA.
Media Contact CureVacThorsten Schuller, Vice President of Communications CureVac, Tubingen, Germany T: 7071 9883-1577thorsten. schueller@curevac. com
Relationships with investors of CureVac Contact Sarah Fakih, Vice President of Investor Relations CureVac, Tubingen, Germany T: 49 7071 9883-1298 M: 49160 496949 sarah. fakih@curevac. com Contact for Latin American journalists Gloria Nio de Rivera Face-to-face projection and Corporate Affairs Care, SC01330 Mexico CityMexicoDirection: 52 55 5292 3568 Mobile phone: 521 55 5076 1524glorianr@facetofacelatam. onmicrosoft. com
Forward-Looking Statements This press release comprises statements that constitute “forward-looking statements” as that term is explained in the United States Private Securities Litigation Reform Act of 1995, adding statements that express opinions, expectations, ideals, plans. , objectives, assumptions or projections. through CureVac (the “Company”) in connection with occasions or long-term effects, as opposed to statements that reflect ancient facts. Examples come with discussion of corporate strategies, financing plans, expansion opportunities, and market position expansion. In some cases, you would possibly identify such forward-looking statements through terminology such as “anticipate”, “intend”, “believe”, “estimate”, “plan”, “seek”, “project” or possibly “anticipate”. “” will “,” could “,” may also simply “,” forward-looking “,” pretend “or” deserve “, the negatives of such terms or expressions. Forward-looking statements are based on ideals and assumptions of control and data that currently exist for the company. However, such forward-looking statements are not promises of the company’s functionality and you deserve not to place undue reliance on such statements. Forward-looking statements are subject to many dangers, uncertainties and other variable circumstances, in addition negative global economic situations and continued ability and volatility in global money market positions, the ability to unload funding, the ability to conduct existing and long-term preclinical and clinical trials, time, expense, and regulatory uncertainty theoretical approval, dependence on third parties and collaborative partners, ability to bring products to market position, habi ability to manufacture products, imaginable adjustments to existing and proposed legislation, government regulations and policies, pressures to expand the festival and consolidation within the corporate industry, the business effects of the COVID-19 pandemic and operational effects the ability to manage expansion, dependence on key personnel, dependence on high-level asset protection, the ability to do some patient protection, and fluctuations in operating effects due to affecting exchange rates or other factors. These dangers and uncertainties could cause the statements to be misleading and readers are cautioned not to place undue reliance on such statements. Many of these hazards are beyond the Company’s control and may also cause their actual effects to differ materially from those expected to occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not assume, and in particular, disclaims any legal responsibility to update such statements or to publicly announce the effects of any revision of such statements to reflect events or long-term developments, unless required by law.
For more information, see the Company’s reports and documents filed with the U. S. Securities and Exchange Commission. U. S. (SEC) You can download those documents by visiting EDGAR at the SEC www. sec. gov.
SOURCE: CureVac N. V.